O	0	6	Levels	Level	NNS	B-NP
O	7	9	of	of	IN	B-PP
O	10	20	expression	expression	NN	B-NP
O	21	23	of	of	IN	B-PP
O	24	29	CYR61	CYR61	NN	B-NP
O	30	33	and	and	CC	I-NP
O	34	38	CTGF	CTGF	NN	I-NP
O	39	42	are	be	VBP	B-VP
O	43	53	prognostic	prognostic	JJ	B-ADJP
O	54	57	for	for	IN	B-PP
B-Cancer	58	63	tumor	tumor	NN	B-NP
O	64	75	progression	progression	NN	I-NP
O	76	79	and	and	CC	I-NP
O	80	88	survival	survival	NN	I-NP
O	89	91	of	of	IN	B-PP
O	92	103	individuals	individual	NNS	B-NP
O	104	108	with	with	IN	B-PP
B-Cancer	109	116	gliomas	glioma	NNS	B-NP
O	116	117	.	.	.	O

O	118	121	The	The	DT	B-NP
O	122	132	biological	biological	JJ	I-NP
O	133	143	properties	property	NNS	I-NP
O	144	146	of	of	IN	B-PP
O	147	150	CCN	CCN	NN	B-NP
O	151	159	proteins	protein	NNS	I-NP
O	160	167	include	include	VBP	B-VP
O	168	179	stimulation	stimulation	NN	B-NP
O	180	182	of	of	IN	B-PP
B-Cell	183	187	cell	cell	NN	B-NP
O	188	201	proliferation	proliferation	NN	I-NP
O	201	202	,	,	,	O
O	203	212	migration	migration	NN	B-NP
O	212	213	,	,	,	O
O	214	217	and	and	CC	O
O	218	226	adhesion	adhesion	NN	B-NP
O	226	227	,	,	,	O
O	228	230	as	as	RB	B-CONJP
O	231	235	well	well	RB	I-CONJP
O	236	238	as	as	IN	I-CONJP
O	239	251	angiogenesis	angiogenesis	NN	B-NP
O	252	255	and	and	CC	I-NP
O	256	269	tumorigenesis	tumorigenesis	NN	I-NP
O	269	270	.	.	.	O

O	271	273	We	We	PRP	B-NP
O	274	284	quantified	quantify	VBD	B-VP
O	285	290	CYR61	CYR61	NN	B-NP
O	290	291	,	,	,	O
O	292	296	CTGF	CTGF	NN	B-NP
O	296	297	,	,	,	O
O	298	302	WISP	WISP	NN	B-NP
O	302	303	-	-	HYPH	B-NP
O	303	304	1	1	CD	I-NP
O	304	305	,	,	,	O
O	306	309	and	and	CC	O
O	310	313	NOV	NOV	NN	B-NP
O	314	318	mRNA	mRNA	NN	I-NP
O	319	329	expression	expression	NN	I-NP
O	330	336	levels	level	NNS	I-NP
O	337	339	in	in	IN	B-PP
B-Cancer	340	347	samples	sample	NNS	B-NP
O	348	352	from	from	IN	B-PP
O	353	358	sixty	sixty	CD	B-NP
O	358	359	-	-	HYPH	I-NP
O	359	362	six	six	CD	I-NP
B-Cancer	363	370	primary	primary	JJ	I-NP
I-Cancer	371	378	gliomas	glioma	NNS	I-NP
O	379	382	and	and	CC	O
O	383	387	five	five	CD	B-NP
O	388	394	normal	normal	JJ	I-NP
B-Multi-tissue_structure	395	400	brain	brain	NN	I-NP
I-Multi-tissue_structure	401	408	samples	sample	NNS	I-NP
O	409	414	using	use	VBG	B-VP
O	415	427	quantitative	quantitative	JJ	B-NP
O	428	432	real	real	JJ	I-NP
O	432	433	-	-	HYPH	I-NP
O	433	437	time	time	NN	I-NP
O	438	441	PCR	PCR	NN	I-NP
O	442	447	assay	assay	NN	I-NP
O	447	448	.	.	.	O

O	449	460	Statistical	Statistical	JJ	B-NP
O	461	469	analysis	analysis	NN	I-NP
O	470	473	was	be	VBD	B-VP
O	474	483	performed	perform	VBN	I-VP
O	484	486	to	to	TO	I-VP
O	487	494	explore	explore	VB	I-VP
O	495	498	the	the	DT	B-NP
O	499	504	links	link	NNS	I-NP
O	505	512	between	between	IN	B-PP
O	513	523	expression	expression	NN	B-NP
O	524	526	of	of	IN	B-PP
O	527	530	the	the	DT	B-NP
O	531	534	CCN	CCN	NN	I-NP
O	535	540	genes	gene	NNS	I-NP
O	541	544	and	and	CC	O
O	545	553	clinical	clinical	JJ	B-NP
O	554	557	and	and	CC	I-NP
O	558	570	pathological	pathological	JJ	I-NP
O	571	581	parameters	parameter	NNS	I-NP
O	581	582	.	.	.	O

O	583	597	Overexpression	Overexpression	NN	B-NP
O	598	600	of	of	IN	B-PP
O	601	606	CYR61	CYR61	NN	B-NP
O	606	607	,	,	,	O
O	608	612	CTGF	CTGF	NN	B-NP
O	612	613	,	,	,	O
O	614	618	WISP	WISP	NN	B-NP
O	618	619	-	-	HYPH	B-NP
O	619	620	1	1	CD	I-NP
O	620	621	,	,	,	O
O	622	625	and	and	CC	O
O	626	629	NOV	NOV	NN	B-NP
O	630	638	occurred	occur	VBD	B-VP
O	639	641	in	in	IN	B-PP
O	642	644	48	48	CD	B-NP
O	644	645	%	%	NN	I-NP
O	646	647	(	(	(	O
O	647	649	32	32	CD	B-NP
O	650	652	of	of	IN	B-PP
O	653	655	66	66	CD	B-NP
O	655	656	)	)	)	O
O	656	657	,	,	,	O
O	658	660	58	58	CD	B-NP
O	660	661	%	%	NN	I-NP
O	662	663	(	(	(	O
O	663	665	38	38	CD	B-NP
O	666	668	of	of	IN	B-PP
O	669	671	66	66	CD	B-NP
O	671	672	)	)	)	O
O	672	673	,	,	,	O
O	674	676	36	36	CD	B-NP
O	676	677	%	%	NN	I-NP
O	678	679	(	(	(	O
O	679	681	24	24	CD	B-NP
O	682	684	of	of	IN	B-PP
O	685	687	66	66	CD	B-NP
O	687	688	)	)	)	O
O	688	689	,	,	,	O
O	690	693	and	and	CC	O
O	694	696	15	15	CD	B-NP
O	696	697	%	%	NN	I-NP
O	698	699	(	(	(	O
O	699	701	10	10	CD	B-NP
O	702	704	of	of	IN	B-PP
O	705	707	66	66	CD	B-NP
O	707	708	)	)	)	O
O	709	711	of	of	IN	B-PP
B-Cancer	712	719	primary	primary	JJ	B-NP
I-Cancer	720	727	gliomas	glioma	NNS	I-NP
O	727	728	,	,	,	O
O	729	741	respectively	respectively	RB	B-ADVP
O	741	742	.	.	.	O

O	743	756	Interestingly	Interestingly	RB	B-ADVP
O	756	757	,	,	,	O
O	758	769	significant	significant	JJ	B-NP
O	770	782	associations	association	NNS	I-NP
O	783	787	were	be	VBD	B-VP
O	788	793	found	find	VBN	I-VP
O	794	801	between	between	IN	B-PP
O	802	807	CYR61	CYR61	NN	B-NP
O	808	818	expression	expression	NN	I-NP
O	819	825	versus	versus	IN	B-PP
B-Cancer	826	831	tumor	tumor	NN	B-NP
O	832	837	grade	grade	NN	I-NP
O	837	838	,	,	,	O
O	839	848	pathology	pathology	NN	B-NP
O	848	849	,	,	,	O
O	850	856	gender	gender	NN	B-NP
O	856	857	,	,	,	O
O	858	861	and	and	CC	O
O	862	865	age	age	NN	B-NP
O	866	868	at	at	IN	B-PP
O	869	878	diagnosis	diagnosis	NN	B-NP
O	878	879	.	.	.	O

O	880	884	Also	Also	RB	B-ADVP
O	884	885	,	,	,	O
O	886	887	a	a	DT	B-NP
O	888	899	significant	significant	JJ	I-NP
O	900	911	correlation	correlation	NN	I-NP
O	912	919	existed	exist	VBD	B-VP
O	920	927	between	between	IN	B-PP
O	928	932	CTGF	CTGF	NN	B-NP
O	933	937	mRNA	mRNA	NN	I-NP
O	938	944	levels	level	NNS	I-NP
O	945	951	versus	versus	CC	O
B-Cancer	952	957	tumor	tumor	NN	B-NP
O	958	963	grade	grade	NN	I-NP
O	963	964	,	,	,	O
O	965	971	gender	gender	NN	B-NP
O	971	972	,	,	,	O
O	973	976	and	and	CC	O
O	977	986	pathology	pathology	NN	B-NP
O	986	987	.	.	.	O

O	988	990	In	In	IN	B-PP
O	991	999	contrast	contrast	NN	B-NP
O	1000	1002	to	to	TO	B-PP
O	1003	1008	CYR61	CYR61	NN	B-NP
O	1009	1012	and	and	CC	I-NP
O	1013	1017	CTGF	CTGF	NN	I-NP
O	1017	1018	,	,	,	O
O	1019	1021	no	no	DT	B-NP
O	1022	1033	significant	significant	JJ	I-NP
O	1034	1045	association	association	NN	I-NP
O	1046	1049	was	be	VBD	B-VP
O	1050	1055	found	find	VBN	I-VP
O	1056	1063	between	between	IN	B-PP
O	1064	1074	expression	expression	NN	B-NP
O	1075	1077	of	of	IN	B-PP
O	1078	1084	either	either	CC	O
O	1085	1089	WISP	WISP	NN	B-NP
O	1089	1090	-	-	HYPH	B-NP
O	1090	1091	1	1	CD	I-NP
O	1092	1094	or	or	CC	O
O	1095	1098	NOV	NOV	NN	B-NP
O	1099	1105	versus	versus	IN	B-PP
O	1106	1109	any	any	DT	B-NP
O	1110	1112	of	of	IN	B-PP
O	1113	1116	the	the	DT	B-NP
O	1117	1129	pathological	pathological	JJ	I-NP
O	1130	1138	features	feature	NNS	I-NP
O	1138	1139	.	.	.	O

O	1140	1151	Furthermore	Furthermore	RB	B-ADVP
O	1151	1152	,	,	,	O
O	1153	1156	Cox	Cox	NNP	B-NP
O	1157	1167	regression	regression	NN	I-NP
O	1168	1176	analysis	analysis	NN	I-NP
O	1177	1183	showed	show	VBD	B-VP
O	1184	1188	that	that	IN	B-SBAR
O	1189	1194	CYR61	CYR61	NN	B-NP
O	1195	1198	and	and	CC	I-NP
O	1199	1203	CTGF	CTGF	NN	I-NP
O	1204	1214	expression	expression	NN	I-NP
O	1215	1218	had	have	VBD	B-VP
O	1219	1220	a	a	DT	B-NP
O	1221	1232	significant	significant	JJ	I-NP
O	1233	1244	correlation	correlation	NN	I-NP
O	1245	1249	with	with	IN	B-PP
O	1250	1257	patient	patient	NN	B-NP
O	1258	1266	survival	survival	NN	I-NP
O	1266	1267	.	.	.	O

O	1268	1273	These	These	DT	B-NP
O	1274	1281	results	result	NNS	I-NP
O	1282	1289	suggest	suggest	VBP	B-VP
O	1290	1294	that	that	IN	B-SBAR
O	1295	1300	CYR61	CYR61	NN	B-NP
O	1301	1304	and	and	CC	I-NP
O	1305	1309	CTGF	CTGF	NN	I-NP
O	1310	1313	may	may	MD	B-VP
O	1314	1318	play	play	VB	I-VP
O	1319	1320	a	a	DT	B-NP
O	1321	1325	role	role	NN	I-NP
O	1326	1328	in	in	IN	B-PP
O	1329	1332	the	the	DT	B-NP
O	1333	1344	progression	progression	NN	I-NP
O	1345	1347	of	of	IN	B-PP
B-Cancer	1348	1355	gliomas	glioma	NNS	B-NP
O	1355	1356	;	;	:	O
O	1357	1362	their	their	PRP$	B-NP
O	1363	1369	levels	level	NNS	I-NP
O	1370	1372	at	at	IN	B-PP
O	1373	1382	diagnosis	diagnosis	NN	B-NP
O	1383	1386	may	may	MD	B-VP
O	1387	1391	have	have	VB	I-VP
O	1392	1402	prognostic	prognostic	JJ	B-NP
O	1403	1415	significance	significance	NN	I-NP
O	1415	1416	;	;	:	O
O	1417	1420	and	and	CC	O
O	1421	1426	these	these	DT	B-NP
O	1427	1435	proteins	protein	NNS	I-NP
O	1436	1441	might	might	MD	B-VP
O	1442	1447	serve	serve	VB	I-VP
O	1448	1450	as	as	IN	B-PP
O	1451	1459	valuable	valuable	JJ	B-NP
O	1460	1467	targets	target	NNS	I-NP
O	1468	1471	for	for	IN	B-PP
O	1472	1483	therapeutic	therapeutic	JJ	B-NP
O	1484	1496	intervention	intervention	NN	I-NP
O	1496	1497	.	.	.	O

